Skip to content

Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients

Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06709157
Enrollment
200
Registered
2024-11-29
Start date
2024-12-10
Completion date
2025-06-01
Last updated
2024-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Keywords

HIV, immunocompromised, cytokines

Brief summary

Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease, including 0.3 million people with human immunodeficiency virus (HIV) infection . TB remains the primary killer of HIV-positive individuals. TB incidence is falling at about 2% per year . Airborne transmission of M. tuberculosis typically causes TB infection in both immunocompetent and immunocompromised hosts and the disease is symptomatic and contagious .

Detailed description

TB and HIV infections are strictly linked together. TB is the most common opportunistic infection and causes high morbidity rate among people living with HIV. Because of the decrease in cell-mediated immunity, HIV alters the pathogenesis of TB, thereby expressively increasing the risk of TB in HIV-positive patients and eventually leading to more severe complications and forms of TB.

Interventions

DIAGNOSTIC_TESTP24 antigens and antibody

estimation of antigens and antibodies to diagnose HIV

DIAGNOSTIC_TESTzeihl - Nelsen stain

staining sputum from patients with HIV to detect tubercle bacilli

DIAGNOSTIC_TESTculture on Lowenstein jensen media

spenciem will be inoculated on LJ media and kept for 2-8 weeks, to see small white colonies

to see the pattern of antibiotic resistance of tubercle bacilli

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients with chronic chest disease

Exclusion criteria

* Patients with other respiratory or infectious diseases.

Design outcomes

Primary

MeasureTime frameDescription
The Prevalance of tubercuolsis in immunocompetent patients suffereing from chronic chest problemsDecember 2024- June 2025Patients suffering from chronic chest problems will be screened for presence of TB bacilli using chest X-ray, sputum smear, culture on LJ media, detection of DNA of TB bacilli using PCR
The prevalence of tuberculosis in HIV patientsDecember 2024- June 2025Detection of tubercle bacilli in HIV positive patients , these patients will be screened for presence of TB bacilli using chest X-ray, sputum smear, culture on LJ media, detection of DNA of TB bacilli using PCR

Countries

Egypt

Contacts

Primary ContactNoha S Shafik, Lecturer
Nohasaber@med.sohag.edu.eg0201067261504
Backup ContactMona Lecturer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026